Has Loyda Torres Berrios, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,171 in general payments to Loyda Torres Berrios, MD across 33 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Loyda Torres Berrios, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Loyda Torres Berrios, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Loyda Torres Berrios, MD

Dermatology · Bayamon, PRNPI 1912975624

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,624 of the $2,171 with a category attached, or 74.8%. It is spread thinly across 9 manufacturers, the largest accounting for just 22.9%. Reporting peaked in 2022 at $519 and has fallen 77.3% since, to $118 in 2025.

$2,171in general payments, 2019–2025

Across 33 payments — averaging $65.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$496
Sanofi$356
AbbVie$333
E.r. Squibb & Sons, L.L.C.$318
Amgen$287
Lilly USA, LLC$237
plus $144 from 3 others

What the payments were for

Food & beverage$1,62475%
Education$54625%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	5	$496
Sanofi	4	$356
AbbVie	9	$333
E.r. Squibb & Sons, L.L.C.	3	$318
Amgen	3	$287
Lilly USA, LLC	2	$237
Novartis	4	$66
Pfizer	2	$50
Eli Lilly Export S.A. Puerto Rico Branch	1	$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

DUPIXENT$454
Sotyktu$239
Skyrizi$125
Humira$119
EBGLYSS$118

How this compares

$2,171 in reported general payments places this provider in the 55th percentile of 108 dermatology providers in Puerto Rico.

See all dermatology providers in Puerto Rico →

Medicare billing

Part B allowed, 2024

$4,352

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Humira(Cf) PenAdalimumab	29	$249,479
Dupixent PenDupilumab	31	$117,679
OtezlaApremilast	14	$69,635
Amjevita(Cf) AutoinjectorAdalimumab-Atto	19	$40,863
Hadlima(Cf) PushtouchAdalimumab-Bwwd	11	$13,365
Calcipotriene	32	$4,252
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc	111	$3,723
Fluorouracil	44	$3,622
Clobetasol Propionate	94	$3,145
Ciclopirox	62	$2,489
Minocycline Hcl	40	$2,171
Metronidazole	43	$2,083
Desonide	17	$2,036
Ketoconazole	73	$1,533
Desloratadine	67	$1,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AmgenOtezla	$287	$69,63514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 108 dermatology providers in Puerto Rico.

Other dermatology in Bayamon

See the full list for Puerto Rico →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →